DOCSLIB.ORG

Adler, Lawrence Ali, Munaf Alphs, Larry Altstiel, Larry Apter, Jeffrey Atkins, Alexandra Averill, Lynnette Awad, George Bain, Ea

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Adler, Lawrence Ali, Munaf Alphs, Larry Altstiel, Larry Apter, Jeffrey Atkins, Alexandra Averill, Lynnette Awad, George Bain, Ea Adler, Lawrence Ali, Munaf Alphs, Larry University of Maryland School of Medicine Munaf Ali Consultancy Ltd Janssen Phamaceutical 22 S. Greene St. 16 Station Hill Hayes 1125 Trenton Harbourton Road S12A08 Kent, BR27DJ United Kingdom Titusville, New Jersey 08560 USA Baltimore, Maryland 21201 USA Altstiel, Larry Apter, Jeffrey Atkins, Alexandra vTv Therapeutics Princeton Medical Institute Neurocog Trials 4170 Mendenhall Oaks Pkwy 256 Bunn Drive 3211 Shannon Road High Point, North Carolina 27265 USA Suite 6 Durham, North Carolina 27707 USA Princeton, New Jersey 08540 USA Averill, Lynnette Awad, George Bain, Earle Yale University/National Center for PTSD- University of Toronto AbbVie Clinical Neurosciences Division 2175 Keele Street 1 North Waukegan Road 950 Campbell Avenue 151E Suite 243A Dept R48B, Bldg. AP4/B West Haven, Connecticut 06511 USA Toronto, Ontario M6M 3Z4 Canada North Chicago, Illinois 60064 USA Berkowitz, Linda Berman, Robert Bhaskar, Sailaja Bracket Biohaven Pharmaceuticals Noven Pharmaceuticals, Inc. 575 E. Swedesford Rd 77 Livingston Street 350 5th Avenue Suite 200 New Haven, Connecticut 06511 USA 37th Floor Wayne, Pennsylvania 19087 USA New York, New York 10118 USA Binneman, Brendon Bonson, Katherine Bose, Anjana Pfizer FDA Alkermes, Inc 610 Main Street 10903 New Hampshire Ave 852 Winter Street 5th Floor WO 51 RM 5110 Waltham, Massachusetts 02451 USA Cambridge, Massachusetts 02139 USA Silver Spring, Maryland 20993 USA Bowden, Charles Bower, Colin Brady, Linda UT Health Science Center at San Antonio Bracket NIH/NIMH/DNBBS 7703 Floyd Curl 575 East Swedesford Road Suite 200 6001 Executive Blvd, NSC San Antonio, Texas 78229 USA Wayne, Pennsylvania 19087 USA Room 7204 Bethesda, Maryland 20892 USA Brady, Chris Breier, Alan Brown, Brianne inVentiv Health Clinical Indiana University Janssen 1001 Winstead Dr. Neuroscience Building 1125 Trenton Harbourton Road Cary, North Carolina 27513 USA W. 15th Street, Suite 200D Titusville, New Jersey 08560 USA Indianapolis, Indiana 46202 USA Brownstein, Lawrence Bryson, Heather Bugarski-Kirola, Dragana AiCure PPD Granta Park F. Hoffmann-La Roche Ltd 104 Chinaberry Great Abington, Cambridge Grenzacherstrasse 124 Lafayette, Pennsylvania 19444 USA CB21 6GQ United Kingdom 4070 Basel, Switzerland Burch, Daniel Busner, Joan Butler, Adam PPD Bracket Bracket 3900 N Paramount Pkwy 575 E. Swedesford Rd 575 E. Swedesford Rd Morrisville, North Carolina 27560 USA Suite 200 Suite 200 Wayne, Pennsylvania 19087 USA Wayne, Pennsylvania 19087 USA Canuso, Carla Cappelleri, Joseph Carpenter, David Janssen Research & Development Pfizer Inc Dart NeuroScience, LLC 1125 Trenton-Harbourton Road 445 Eastern Point Road 12278 Scripps Summit Drive Titusville, New Jersey 08560 USA MS 8260-2502 San Diego, California 92131 USA Groton, Connecticut 06340 USA Carter, Monique Chappell, Phillip Cipriani, Andrea Pfizer, Inc Pfizer, Inc University of Oxford, Dept of Psychiatry 500 Arcola Road 445 Eastern Point Road Warneford Hospital G4306 Groton, Connecticut 06340 USA Warneford Lane Collegeville, Pennsylvania 19426 USA Oxford OX3 7JX United Kingdom Colman, Tom Connelly, Kimberly Coric, Vlad Nauset Consulting, LLC MedAvante Biohaven Pharmaceuticals 322 Fitzwater Street 100 American Metro Blvd 234 Church Street Philadelphia, Pennsylvania 19147 USA Suite 106 Suite 304 Hamilton, New Jersey 08619 USA New Haven, Connecticut 06510 USA Cubbin, Thomas Cucchiaro, Josephine Dakshanamurthy, Sivanesan Alkermes Sunovion Pharmaceuticals, Inc Georgetown University Medical Center 852 Winter Street 1 Bridge Plaza 3900 Reservoir Rd Waltham, MA 02451 Suite 510 E401 NRB Fort Lee, New Jersey 07024 USA Washington, District of Columbia 20057 USA Daniel, David Davidson, Michael Davis, John Bracket Tel Aviv University University of Illinois at Chicago 575 E. Swedesford Rd 11 B Nitzana Street 1601 West Taylor Street Suite 200 Tel Aviv, 68117 Israel Chicago, Illinois 60612 USA Wayne, Pennsylvania 19087 USA Davis, Vicki Detke, Michael Diaz, Melanie NeuroCog Trials Detke Biopharma Consulting, LLC INC Research 3211 Shannon Road Indiana University School of Medicine 15614 Berea Drive Suite 300 5018 St. Charles Place Odessa, Florida 33556 USA Durham, North Carolina 27707 USA Carmel, Indiana 46033 USA Docherty, John Dorffner, Georg D'Souza, Bernadette Otsuka Medical University of Vienna Midwest Clinical Research,LLC 508 Carnegie Center Drive Section for Artificial Intelligence 711 Old Ballas, Suite 106 Princeton, New Jersey 08540 USA CeMSIIS Creve Coeur, Missouri 63141 USA Freyung 6/2 Vienna, 1210 Austria Dubé, Sanjay DuBrava, Sarah Dunn, Walter Avanir Pharmaceuticals, Inc. Pfizer, Inc Greater LA VA/ UCLA 30 Enterprise 445 Eastern Point Rd 11301 Wilshire Blvd Suite 400 MS 8260-2224 Bld 210A, Rm 130 Aliso Viejo, California 92656 USA Groton, Connecticut 06340 USA Los Angeles, California 90073 USA Ellis, Amy Engelhardt, Nina Ereshefsky, Larry MedAvante, Inc Cronos PAREXEL International 100 American Metro Blvd 201 S Main Street 143 Voyage Mall Suite 106 Lambertville, New Jersey 08530 USA Marina del Rey, California 90292 USA Hamilton, New Jersey 08619 USA Evans, Rebecca Evenden, John Facheris, Maurizio Parexel Cambridge Cognition AbbVie 1 Federal Street 2750 Rasmussen Road 1 North Waukegan Billerica, Massachusetts 01821 USA Park City, Utah 84098 USA AP31-1 North Chicago, Illinois 60064 USA Faison, Warachal Farchione, Tiffany Farokhnia, Mehdi Pfizer, Inc US FDA NIAAA and NIDA, NIH 235 East 42nd Street (235/4/62) 10903 New Hampshire Ave 10 Center Drive (10CRC/15330) New York, New York 10017 USA Bldg 22, Rm 4110 Room 1-5413 Silver Spring, Maryland 20903 USA Bethesda, Maryland 20892 USA Ferziger, Reuven Forray, Carlos Frangou, Sophia Merck Lundbeck, LLC Icahn School of Medicine at Mount Sinai 12429 Kemp Mill Road 215 College Road Department of Psychiatry Silver Spring, Maryland 20902 USA Paramus, New Jersey 07676 USA 1425 Madison Ave New York, New York 10029 USA Fu, Dong Jing Fuller, Doris Gault, Laura Janssen Scientific Affairs, LLC Treatment Advocacy Center AbbVie 1125 Trenton-Harbourton Rd 200 N. Glebe Road, #801 100 Abbott Park Titusville, New Jersey 08560 USA Arlington, Virginia 22203 USA North Chicago, Illinois 60064 USA Geerts, Hugo Georgiades, Anastasia Gibertini, Michael In Silico Biosciences Duke University School of Medicine INC Research 686 Westwind Dr 3211 Shannon Rd #300 5707 Southwest Parkway Berwyn, Pennsylvania 19312 USA Durham, North Carolina 27707 USA Bldg 2, Suite 200 Austin, Texas 78704 USA Gilbert, Paul Goff, Donald Gogtay, Nitin MedAvante, Inc NYU School of Medicine NIMH 100 American Metro Blvd One Park Ave 6001 Executive Blvd. Suite 106 Rm 8-212 Bethesda, Maine 20892 USA Hamilton, New Jersey 08619 USA New York, New York 10025 USA Goldensohn, Ivan Goldman, Robert Grabb, Margaret Cronos CCS, Inc Sunovion National Institute of Mental Health 201 S Main Street 1 Bridge Plaza North 6001 Executive Blvd Suite 1 Ft Lee, New Jersey 07024 USA Rockville, Maryland 20871 USA Lambertville, New Jersey 08530 USA Gwin, Keva Hagi, Katsuhiko Haig, George H. Lundbeck A/S Sumitomo Dainippon Pharma Co., Ltd. AbbVie 4 Parkway N 13-1, Kyobashi 1 North Waukegan Road Deerfield, Illinois 60015 USA 1-Chome Neurosciences Development Dept Chuo-ku, 104-8356 Japan AP4-1 North Chicago, Illinois 60064 USA Hanina, Adam Harkavy-Friedman, Jill Hart, Jennifer AiCure American Foundation for Suicide Prevention Duke University 902 Broadway, 6th Floor 120 Wall Street 300 West Morgan Street New York, New York 10010 USA 29th Floor Suite 800 New York, New York 10005 USA Durham, North Carolina 27701 USA Hartman, Ger Hartman, Richard Haynes, Ginger Julius Clinical B.V. NeurWrite LLC Eli Lilly and Company Broederplein 41 3 Brookfield Way 3057 Oakleigh Manor Cove Zeist, 3703 CD Netherlands Morristown, New Jersey 07960-5136 USA Germantown, Tennessee 38138 USA Heinssen, Robert Hendrix, Suzanne Henningfield, Jack National Institute of Mental Health Pentara Corporation Pinney Associates 6001 Executive Blvd 2180 E. Claybourne Ave 4800 Montgomery Lane Bethesda, Maryland 20892 USA Salt Lake City, Utah 84109 USA Suite 400 Bethesda, Maryland 20814 USA Hirata, Yuko Hoffmeyer, Debra Hufford, Michael INC Research CITrials Pinney Associates 720 King Street 7th Floor 1675 Scenic Avenue, Suite 100 201 North Craig Street Toronto, Ontario M5V 2T3 Canada Costa Mesa, California 92626 USA Suite 320 Pittsburgh, Pennsylvania 15213 USA Hughes, Christina Hulihan, Joe Janikowski, Bartosz Bracket Paradigm Consulting, LLC WCT 575 East Swedesford Rd 201 N Congress St Randova 4 Suite 200 Newtown, Pennsylvania 18940 USA Praha 5, 150 00 Czech Republic Wayne, Pennsylvania 19087 USA Johnson, Julleah Kalali, Amir Kando, Judith Otsuka Pharmaceutical Development & Quintiles Shire Commercialization, Inc 10188 Telesis Court 300 Shire Way 103 Mornay Ln San Diego, California 92121 USA Lexington, Massachusetts 02421 USA Little Rock, Arkansas 72223 USA Kane, John Kasuba, Bryce Keefe, Richard Northwell Health INC Research Duke University Medical Center 75-59 263rd Street 40 E. Benedict Ave Department of Psychiatry Glen Oaks, New York 11004 USA Suite 102 Box 3270 Havertown, Pennsylvania 19083 USA Durham, North Carolina 27710 USA Keim, Kevin Kerwin, Maria Khan, Anzalee INC Research, LLC Bracket Manhattan Psychiatric Center 3201 Beechleaf Court 575 E. Swedesford Rd 1 Wards Island Complex Suite 600 Suite 200 Wards Island, New York 10035 USA Raleigh, North Carolina 27604 USA Wayne, Pennsylvania 19087 USA Klein, Michael Komorowsky, Andrew Kott, Alan FDA Worldwide Clinical Trials Bracket 10903 New Hampshire Ave 1000 Continental
Load more

Recommended publications
  • Honoring Catalysts in Action Over the Winter and Spring Through Our Website, Facebook and Twitter
    8 CONNEC TCFS We have been honored to share the stories of 25 Catalysts Honoring Catalysts in Action over the winter and spring through our website, Facebook and Twitter. We hope you’ll take time to read about their remarkable lives and the courage and persistence they Throughout this issue of SolveCFS we pay tribute to the collective action demonstrate every day. As unique as each one is, they are united in their hope that research led by the CFIDS that has led up to the launch of the Association’s latest research initiative: Association of America will lead to better treatment and the research institute without walls (RIWW). Two individuals warrant spe - healthier futures. cial attention for their immensely important contributions. First, James York , the first person consented and enrolled to participate in the SolveCFS BioBank. James was working as an underwater camera man and marine coordinator in the film industry when pneumonia turned into CFS in 2004. He has turned to writing when cognitive impairment can be kept at bay, as a form of expression and, occasionally, compensation. James enrolled in the BioBank as soon as it was announced. He returned his signed consent James York, adrift and at work on the form promptly; completed the extensive medical award-winning film “Ocean Men: Extreme history questionnaire thoroughly and expeditiously Dive” with an IMAX Mark II camera and even recruited his own matched control to partici - housing in Stargate Cave on Andros Island pate. He gave blood samples and tissue swabs. He did in the Bahamas. The picture explored the so as part of an odyssey to learn about CFS and cope beauty and science of breath-hold diving with it.
    [Show full text]
  • AMERICAN HELLENIC CHAMBER of COMMERCE Amcham.Gr
    2018-11-15_ASPROFOS_ADS_01_outline.pdf 1 15/11/2018 7:28:55 μμ C M Y CM MY CY CMY K AMERICANHELLENIC CHAMBER OF C OMMERCE amcham.gr KTX Directory AmCham fin.indd 1 9/11/2018 1:37:03 μμ .PRESS Integrated kitchen & bathroom solutions CHAMBER 60 years of expertise European manufacturing footprint Global presence in 65 countries PYRAMIS METALLOURGIA Α.Ε. 17th km Thessaloniki - Serres | P.O. Box 10 278 | 54110, Thessaloniki, Greece follow us @PyramisGroup Τel.: +30 23940 56700 | Fax.: +30 23940 71134 | [email protected] | www.pyramisgroup.com .PRESS Integrated kitchen & bathroom solutions CHAMBER 60 years of expertise European manufacturing footprint Global presence in 65 countries PYRAMIS METALLOURGIA Α.Ε. 17th km Thessaloniki - Serres | P.O. Box 10 278 | 54110, Thessaloniki, Greece follow us @PyramisGroup Τel.: +30 23940 56700 | Fax.: +30 23940 71134 | [email protected] | www.pyramisgroup.com 2018-11-15_ASPROFOS_ADS_01_outline.pdf 1 15/11/2018 7:28:55 μμ C M Y CM MY CY CMY K AMERICANHELLENIC CHAMBER OF C OMMERCE amcham.gr KTX Directory AmCham fin.indd 1 9/11/2018 1:37:03 μμ DIRECTORY 2019 AMERICANHELLENIC CHAMBER OF COMMERCE amcham.gr KTX_SPENDEO_20,8x28_Final.pdf 1 16/11/18 11:14 π.µ. 2 | DIRECTORY 2019 KTX_SPENDEO_20,8x28_Final.pdf 1 16/11/18 11:14 π.µ. contents U.S. PAGES 105 The United States Government in Greece ..... 106 The Commercial Service U.S. Embassy Athens...................... 108 U.S. Government Agencies and Offices ...... 110 Business and Professional Organizations in the United States ....................... 112 American Chambers of Commerce CHAMBER PAGES 17 in Europe ...............................
    [Show full text]
  • Molecular Medicine Tri-Conference
    Register by January 15 and SAVE up to $200 Premier Sponsors Corporate Sponsors Conference: February 3-5 | Exhibits: February 3-4 Moscone North Convention Center | San Francisco, CA PLENARY KEYNOTES When Drug Research is Personal John F. Crowley, Founder, Novazyme Pharmaceuti cals, Inc. Technology, Aging, and the Brain Biotechnologies GmbH ® Gary W. Small, M.D., Professor, Meso Scale Discovery David Geff en School of Medicine, University of California, Los Angeles Chips, Clones and Living Beyond 100 Paul J.H. Schoemaker, Ph.D., Lead Sponsoring Publicati ons M.B.A., Professor, Wharton School of Business Corporate Support Sponsors Co - Sponsors The State of California Cambridge Healthtech Institute • 250 First Avenue, Suite 300, Needham, MA 02494 Telephone: 781-972-5400 or Toll-Free in the U.S. 888-999-6288 • Fax: 781-972-5425 Tri-Conference.com Media Partners CONFERENCE-AT-A-GLANCE Tuesday, February 2 The Open Access Publisher 8:00 AM Morning Short Course Registration and Coffee 9:00 - 12:00 PM Morning Short Courses (Courses 1-6) 10:15 - 10:30 Networking Coffee Break 1:00 - 2:00 Afternoon Short Course Registration 2:00 - 5:00 Afternoon Short Courses (Courses 7-12) 3:15 - 3:30 Networking Refreshment Break 5:00 Close of Day Wednesday, February 3 7:00 AM Registration and Morning Coffee 8:00 - 9:40 Plenary Keynotes 9:40 - 11:00 Grand Opening Refreshment Break in the Exhibit Hall Nanomedicine 11:00 - 12:40 PM Concurrent Channels 12:40 - 1:45 Sponsored Luncheon Presentations or Lunch on Your Own 1:45 - 2:15 Dessert in the Exhibit Hall 2:15 - 4:20
    [Show full text]
  • The Intellectual Property, Licensing, and Business Development Event of the Year
    CLP & CPEEarn Credit CLE, OCTOBER 14 –17 Sheraton Centre Toronto Toronto, ON, Canada The Intellectual Property, Licensing, and Business Development Event of the Year FEATURING THESE CUTTING-EDGE TOPICS: Connecting & Collaborating: The Convergence of Life Sciences and High Tech Carving Out Your Commercial Space — Strategies and Trade Offs Is High Tech Crazy? Are We Experiencing a Patent Bubble? Benches Unleashed: Judicial Views on Fixing the Systems The Role of IP in Rebuilding Economies Following the Arab Spring How Outcomes of Patent Fights have Changed the Course of History REGISTER BY JULY 31 & SAVE $200! www.LE S2012.org WHO SHOULD ATTEND: Don’t Miss Your Opportunity Professionals to Connect and Collaborate involved with: Business Join more than 1,000 of your colleagues for the LES 2012 Annual Meeting, Development October 14 –17 in Toronto. Intellectual Property The LES Annual Meeting is the must-attend IP, licensing, and business development event Investments of the year — featuring 3½ days of high-quality educational sessions, ample networking Legal opportunities and the industry’s leading Tech Fair. Licensing Open Innovation Fuel Your Network Technology Transfer The LES Annual Meeting provides ample opportunities to connect with your colleagues. R&D Various events, including receptions, breakfasts, lunches and breaks, will allow you to discuss your day-to-day challenges and unique issues with other licensing professionals from around the world. You’re sure to learn tips, tactics and strategies that you can apply From the following back at your workplace. industries: Biotechnology Chemicals & Discover New Resources and Solutions Materials The LES Annual Meeting Tech Fair on October 16 is a vital extension of the educational program and represents a valuable opportunity to cultivate resources that will help you Consumer Products and your organization stay ahead of the competition.
    [Show full text]
  • Drug Repositioning: Extracting Added Value from Prior R&D Investments
    Drug Repositioning: Extracting Added Value from Prior R&D Investments Hermann A.M. Mucke, Ph.D. InsightPharmaReports.com Drug Repositioning: Extracting Added Value from Prior R&D Investments Hermann A.M. Mucke, Ph.D. Published in July 2010 by Cambridge Healthtech Institute • www.InsightPharmaReports.com • Reproduction prohibited i Insight Pharma Reports is a division of Cambridge Healthtech Institute, a world leader in life science information and analysis through conferences, research reports, and targeted publications. Insight Pharma Reports focus on pharmaceutical R&D—the technologies, the companies, the markets, and the strategic business impacts. They regularly feature interviews with key opinion leaders; surveys of the activities, views, and plans of individuals in industry and nonprofit research; and substantive assessments of technologies and markets. Managers at the top 50 pharma companies, the top 100 biopharma companies, and the top 50 vendors of tools and services rely on Insight Pharma Reports as a trusted source of balanced and timely information. Related Report Data Mining in Drug Development and Translational Medicine by Hermann A.M. Mucke, Ph.D. General Manager: Alfred R. Doig, Jr. 781-972-1348, [email protected] Editorial Operations Director: Laurie Sullivan 781-972-1353, [email protected] Design Director: Tom Norton 781-972-5440, [email protected] Production Director: Ann Handy 781-972-5493, [email protected] Marketing Manager: James Prudhomme 781-972-5486, [email protected] Customer Service: Rose LaRaia 781-972-5444, [email protected] Corporate Subscriptions: David Cunningham 781-972-5472, [email protected] Global Report Sales: Jack Valeri 781-972-1355, [email protected] Insight Pharma Reports, 250 First Ave., Suite 300, Needham, MA 02494 www.InsightPharmaReports.com ii • www.InsightPharmaReports.com • Reproduction prohibited Drug Repositioning: Extracting Added Value from Prior R&D Investments Hermann A.M.
    [Show full text]
  • Digital R&D: the Next Frontier for Biopharmaceuticals
    Digital R&D │ The Next Frontier for Biopharmaceuticals The Next Frontier Digital R&D The Next Frontier for Biopharmaceuticals Pharmaceuticals and Medical Products Practice 2017 Designed by the US Design Center Copyright © McKinsey & Company, Inc. www.mckinsey.com Digital R&D The Next Frontier for Biopharmaceuticals 2017 Editors Sastry Chilukuri Ann Westra For more info please contact [email protected] Contents 1 Digital in R&D—the $100 billion opportunity Sastry Chilukuri, Edd Fleming, and Ann Westra R&D in the age of analytics 13 Real-world evidence: From activity to impact Olivia Cavlan, Sastry Chilukuri, Matthias Evers, and Ann Westra 31 Randomized pragmatic trials: Can they fulfill their promise? Arnaub Chatterjee, Sastry Chilukuri, Michael Pencina, Eric Peterson, Saif Rathore, and Vijay Vaidya 35 The next generation in clinical operations performance Sastry Chilukuri, Edd Fleming, Eoin Leydon, Fareed Melhem, and Michael Steinmann 47 Moving beyond serendipity in drug discovery Sastry Chilukuri, Leeland Ekstrom, Jonathan Usuka, and Ann Westra 61 Digital vigilance: Building the backbone for insight-driven safety Kate Chavez and Brandon Parry 69 How big data can revolutionize pharmaceutical R&D Jamie Cattell, Sastry Chilukuri, and Michael Levy Connecting with the individual customer 85 Medical affairs: Key imperatives for engaging and educating physicians in a digital world Matthias Evers, Ivan Ostojic, Brindan Suresh, Josh Weiner, and Ann Westra 101 Engaging patients during clinical trials Montana Cherney, Amit Paley, Leslie Ruckman,
    [Show full text]
  • Top 100 AI Leaders in Drug Discovery and Advanced Healthcare Introduction
    Top 100 AI Leaders in Drug Discovery and Advanced Healthcare www.dka.global Introduction Over the last several years, the pharmaceutical and healthcare organizations have developed a strong interest toward applying artificial intelligence (AI) in various areas, ranging from medical image analysis and elaboration of electronic health records (EHRs) to more basic research like building disease ontologies, preclinical drug discovery, and clinical trials. The demand for the ML/AI technologies, as well as for ML/AI talent, is growing in pharmaceutical and healthcare industries and driving the formation of a new interdisciplinary industry (‘data-driven healthcare’). Consequently, there is a growing number of AI-driven startups and emerging companies offering technology solutions for drug discovery and healthcare. Another important source of advanced expertise in AI for drug discovery and healthcare comes from top technology corporations (Google, Microsoft, Tencent, etc), which are increasingly focusing on applying their technological resources for tackling health-related challenges, or providing technology platforms on rent bases for conducting research analytics by life science professionals. Some of the leading pharmaceutical giants, like GSK, AstraZeneca, Pfizer and Novartis, are already making steps towards aligning their internal research workflows and development strategies to start embracing AI-driven digital transformation at scale. However, the pharmaceutical industry at large is still lagging behind in adopting AI, compared to more traditional consumer industries -- finance, retail etc. The above three main forces are driving the growth in the AI implementation in pharmaceutical and advanced healthcare research, but the overall success depends strongly on the availability of highly skilled interdisciplinary leaders, able to innovate, organize and guide in this direction.
    [Show full text]
  • MMM2013 Finalists.Indd
    GlimpseGlimpse Aatat panel of 100 esteemed industryGoldGold leaders and thinkers spent several hours discussing, reviewing and scoring around 700 entries to the MM&M Awards. Here are the results of their e orts—the 2013 fi nalists ollowing two exhaustive rounds of scoring by 100 or so inde- Make no mistake. Judging the MM&M Awards is a serious business. pendent industry judges, the results are in for the MM&M If you need further proof, take a look at some of the photographs FAwards 2013. The nalists for each category are revealed on from the judging day (pages 62-66), each conveying the dedication the following pages—but you’ll have to wait for the spectacular and hard work that goes into the review process. dinner and ceremony on October 2, 2013 to nd out who will take It’s not enough for a submission simply to look good, either—it home the gold and silver awards. must also be effective. That’s why, as well as assembling a band of The MM&M Awards are judged with the utmost independence seasoned creatives, we recruited more than 30 marketing and brand- and authority, using ing execs from the pharma industry to further extend the authority an esteemed panel of and credibility of the judging process. (See opposite for a complete leaders and thinkers list of 2013 judges.) MMM representing a wide We would like to take this opportunity to thank all of our judges variety of disciplines and for their efforts. backgrounds within the As usual, the identities of all gold and silver winners will be withheld 2013 healthcare marketing until the spectacular gala dinner at Cipriani 42nd Street on October community.
    [Show full text]
  • Past Attendees Have Represented
    Past attendees have represented: 20/20 GeneSystems 23andMe 5AM Solutions, Inc. Abundance Partners Accelerated Cure Project for Multiple Sclerosis Actus Biotechnologies Addario Lung Cancer Medical Institute Addi and Cassi Fund Adenoid Cystic Carcinoma Research Foundation Ader Investment Management Aeras Global TB Vaccine Foundation aha Group Alberta Cancer Foundation Alexandria University Alliance for Lupus Research Alpha-1 Foundation ALS Therapy Development Institute Alzheimer's Association Alzheimer's Drug Discovery Foundation Amarantus Biosciences, Inc. American Academy of Dermatology Association American Enterprise Institute American Heart Association Apollo Management Apple Tree Partners Ares Management, LLC Arizona State University Arthritis Foundation Asmacure Ltee Aspen Brain Forum Assay Depot Assn of American Publishers/Prof & Scholarly ATP Private Equity Partners Aurec Group Austen BioInnovation Institute Autism Speaks Battelle Bay Area Lyme Fund Bay Area Physical Sciences Oncology Center BayBio BCC Partners Beach Point Capital Beats of Laughter Becton Dickinson Beyond Batten Disease Foundation Beyond The Ask Inc. Biobasix Inc. BioCentury Publications BioCycive BioMotiv BioRings LLC BioStrategies Inc. Biotechnology Industry Organization Biovista, Inc. BLL Partners, LLC Bloomberg/Newsroom Blueprint Medicines Boehringer Ingelheim Pharmaceuticals, Inc. Bonnie J Addario Lung Cancer Foundation Boston Children's Hospital Boston University Brain & Behavior Research Foundation Brain Canada Break Through Cancer Coalition Breakout Labs
    [Show full text]
  • REGISTRO INTEGRATORI Giugno 2009
    REGISTRO INTEGRATORI PER PRODOTTO - aggiornato a giugno 2009 PRODOTTO DITTA CODICE + 37° ERBORISTERIA DOTT. CECCHINI E 06 22130-Y 05 BOMBER CLOROFILLA X AD 09803-Y 1 AL GIORNO INDEL X AD 01032-Y 1 P ERBA VITA E 08 35501-Y 100% CREAPURE DEGUSSA ASOLI FARMACEUTICI X AD 07383-Y 100% CREATINA MONOIDRATA VITAMIN SHOP X AD 09262-Y 100% CREATINA MONOIDRATA BODY EVOLUTION I 07 04501-Y 100% CREATINA PURE FITNESS PRODUCTS X AD 09472-Y 100% DESTOCK LABORATOIRES FORTE' PHARMA M 07 31649-Y 100% EGG PRO EXTRA vg EUROSUP X AD 03547-Y 100% ISO WHEY NEWTRITIONS N 09 40118-Y 100% L-GLUTAMINE FISIOPLUS N 08 31834-Y 100% MALTODEX ULTIMATE ITALIA X AD 03157-Y 100% PREMIUM MELATONIN INTERPHARM HERBES I 07 30545-Y 100% PREMIUM SAW PALMETTO INTERPHARM HERBES E 07 30546-Y 100% PURE PLATINUM WHEY NEWTRITIONS N 09 38800-Y 100% SIERO ISOLATE DIETA & FITNESS N 07 32885-Y 100% WHEY ULTIMATE ITALIA I 06 19388-Y 100% WHEY DELITE AMEFIT I 06 15475-Y 100% WHEY GOLD STANDARD NUTRIZEN N 08 35736-Y 100% WHEY GOLD STANDARD VARI GUSTI NUTRICA N 08 35430-Y 100% WHEY PROTEIN SPORT E FITNESS N 09 38814-Y 100% WHEY PROTEIN JUST NATURAL X AD 08705-Y 100% WHEY PROTEIN BOOSTER I 06 18526-Y 100% WHEY PROTEIN FUEL ABS I 06 19973-Y 100% WHEY PROTEIN FUEL FAST ENERGY I 06 15830-Y 19 ERBE PHARMA GREEN E 08 33210-Y 19 ERBE ZERMAT LIMITED E 06 19083-Y 2 GLUT AKG MOLDES N 09 41262-Y 20 ERBE LARIX LABORATORI E 09 40372-Y 24 HR PROTEIN SOLUTION FAST ENERGY I 06 18409-Y 3 CARBONE FINOCCHIO PAPAIA FA RO M 07 33944-Y 3 CREA COMPRESE PHARMATEAM N 09 42682-Y 3 P 1 OTI X AD 00315-Y 3 P 2 OTI X AD
    [Show full text]
  • Compliments of Pharmavoice
    ARTIFICIAL INTELLIGENCE SHOWCASE Driving Drug Innovation With AI The global AI market has been showing rapid growth as major pharmaceutical and medical technology companies invest heavily in internal and external AI partnerships. ccording to some reports, more than key objective is to predict which patients are 50% of executives expect broad scale at risk of cardiovascular disease and then de- How Pharma Can Use A AI adoption by 2025. Further, reve- termine the treatments that might work best. nue generated through AI-based solutions in Scientists at Janssen Research & Devel- AI for Drug Innovation the industry is projected to rise at a CAGR opment have found a way to use AI to speed Create internal expertise and of 21.94% and reach $2.199 billion by 2022, the process of discovering new potential treat- according to Frost & Sullivan. Meanwhile a ments. They are using AI to sort through support AI employees with the right report by Global Market Insights forecasts how cells representing certain diseases react resources that the U.S. healthcare AI market will exceed to a variety of compounds. Then, through Collaborate with start-ups and $10 billion by 2024. With total investment collaborations with academic partners, they others using AI in drug discovery exceeding $7.2 billion across 300-plus deals are using computer algorithms to predict how Partner with academic groups that between 2013 and 2018, the pharmaceutical other cells are likely to react to those same focus on AI R&D industry continues to lead the healthcare sector compounds. The benefit for scientists is they in terms of attracting AI-related VC funding.
    [Show full text]
  • Solving the Problem of New Uses by Creating Incentives for Private Industry to Repurpose Off-Patent Drugs
    SOLVING THE PROBLEM OF NEW USES DRAFT 9/15/14 SOLVING THE PROBLEM OF NEW USES BY CREATING INCENTIVES FOR PRIVATE INDUSTRY TO REPURPOSE OFF-PATENT DRUGS Benjamin N. Roin* Sept. 15, 2014 Abstract One of the most dramatic public-policy failures affecting biomedical research is the lack of incentives for industry to develop new therapeutic uses (“indications”) for off-patent drugs—generally known as “the problem of new uses.” Recent technological advances have allowed researchers to identify hundreds of potential new indications for older drugs that could address critical unmet medical needs. And researchers are poised to discover hundreds more. Developing new uses for FDA-approved drugs (known as “drug repurposing”) is much faster, cheaper, and less risky than developing new drugs, and therefore offers what may be the single most promising avenue for delivering new medical treatments to the public. Many commentators argue that a viable business model to support drug repurposing could solve the pharmaceutical industry’s protracted “productivity crisis,” and that it would provide the NIH with a pathway across the proverbial “Valley of Death” in biomedical research. Unfortunately, that business model does not exist. Pharmaceutical companies invariably lose interest in developing new uses for drugs once generics enter the market. The prior scholarship on this problem attributes it to a gap in the patent-based incentives for drug development. But the government already offers patent rights for new uses of existing drugs, which could provide the appropriate incentives for developing those new medical treatments. On paper, these new-use patents give pharmaceutical companies the right to charge payers when physicians prescribe an off-patent drug for a new use without preventing patients from using low-cost generics for the drug’s older, unpatented uses.
    [Show full text]